Vincent Roy

Orleans, 45067, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Acyclic Nucleoside Phosphonate Prodrug LAVR-289 Inhibits Marek's Disease Virus Replication.

Acyclic Nucleoside Phosphonate Prodrug LAVR-289 Inhibits Marek's Disease Virus Replication.

Journal: ACS infectious diseases
Published: May 01, 2026

LAVR-289, a broad-spectrum antiviral, protects immunosuppressed Syrian hamsters against lethal adenovirus challenge.

LAVR-289, a broad-spectrum antiviral, protects immunosuppressed Syrian hamsters against lethal adenovirus challenge.

Journal: Antiviral research
Published: June 03, 2025

Antiviral Activity of the Acyclic Nucleoside Phosphonate Prodrug LAVR-289 against Poxviruses and African Swine Fever Virus.

Antiviral Activity of the Acyclic Nucleoside Phosphonate Prodrug LAVR-289 against Poxviruses and African Swine Fever Virus.

Journal: ACS infectious diseases
Published: May 22, 2025

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo.

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo.

Journal: ACS infectious diseases
Published: May 19, 2025

LAVR-289, an Acyclo-Nucleoside Phosphonate, Has Broad-Spectrum Activity against Herpesviruses.

LAVR-289, an Acyclo-Nucleoside Phosphonate, Has Broad-Spectrum Activity against Herpesviruses.

Journal: ACS infectious diseases
Published: May 17, 2025

Synthesis and Antiviral Evaluation of 5-(4-Aryl-1,3-butadiyn-1-yl)-uridines and Their Phosphoramidate Pronucleotides.

Synthesis and Antiviral Evaluation of 5-(4-Aryl-1,3-butadiyn-1-yl)-uridines and Their Phosphoramidate Pronucleotides.

Journal: Molecules (Basel, Switzerland)
Published: November 20, 2024

Lyotropic liquid crystal emulsions of LAVR-289: Influence of internal mesophase structure on cytotoxicity and in-vitro antiviral activity.

Lyotropic liquid crystal emulsions of LAVR-289: Influence of internal mesophase structure on cytotoxicity and in-vitro antiviral activity.

Journal: International journal of pharmaceutics
Published: May 27, 2024

Synthesis of LAVR-289, a new [(Z)-3-(acetoxymethyl)-4-(2,4-diaminopyrimidin-6-yl)oxy-but-2-enyl]phosphonic acid prodrug with pronounced antiviral activity against DNA viruses.

Synthesis of LAVR-289, a new [(Z)-3-(acetoxymethyl)-4-(2,4-diaminopyrimidin-6-yl)oxy-but-2-enyl]phosphonic acid prodrug with pronounced antiviral activity against DNA viruses.

Journal: European journal of medicinal chemistry
Published: March 14, 2024

Antibiotics and Antibiotic Resistance-Mur Ligases as an Antibacterial Target.

Antibiotics and Antibiotic Resistance-Mur Ligases as an Antibacterial Target.

Journal: Molecules (Basel, Switzerland)
Published: July 29, 2023

Cobalt-assisted route to rare carbocyclic C-ribonucleosides.

Cobalt-assisted route to rare carbocyclic C-ribonucleosides.

Journal: RSC advances
Published: July 21, 2023

Synthesis and Structure-Activity Relationship Studies of Pyrido [1,2-e]Purine-2,4(1H,3H)-Dione Derivatives Targeting Flavin-Dependent Thymidylate Synthase in Mycobacterium tuberculosis.

Synthesis and Structure-Activity Relationship Studies of Pyrido [1,2-e]Purine-2,4(1H,3H)-Dione Derivatives Targeting Flavin-Dependent Thymidylate Synthase in Mycobacterium tuberculosis.

Journal: Molecules (Basel, Switzerland)
Published: September 06, 2022

Chemical Approaches to Carbocyclic Nucleosides.

Chemical Approaches to Carbocyclic Nucleosides.

Journal: Chemical record (New York, N.Y.)
Published: December 01, 2021
Showing 1-12 of 33

Last Updated: 09/26/2026